MDM2 and non-small cell lung carcinoma: Although recently a genome‐wide CRISPR‐Cas9‐based genetic screening study was carried out with the GeCKO library in the NCI‐H460, A549 and NCI‐H1299 human NSCLC cell lines that identified MDM2, a nuclear‐localised E3 ubiquitin ligase encoding gene, as a potential therapeutic target, these cells were not cisplatin resistant [34].